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 Agranulocytosis during treatment of chronic hepatitis C 
complicated by hyperthyreosis. Case reports
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Abstract
Agranulocytosis is a life-threatening disorder characterised by a greatly decreased number of circulating neutrophils below 500/µL. This 
article presents two cases of agranulocytosis in patients treated with pegylated interferon and ribavirin due to chronic hepatitis C. Inter-
feron induced hyperthyroidism, which required the use of a tyreostatic. Anti-thyroid drugs (ATD) used to treat hyperthyroidism can cause 
agranulocytosis. The synergistic reaction of ATD and interferon on bone marrow cannot be excluded. (Pol J Endocrinol 2012; 63 (1): 52–55)
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Streszczenie
Agranulocytoza jest stanem bezpośredniego zagrożenia życia rozpoznawanym, gdy liczba granulocytów obojętnochłonnych jest niższa 
niż 500/µl. Przedstawiono dwa przypadki ostrej agranulocytozy, która wystąpiła u pacjentów leczonych pegylowanym interferonem i ry-
bawiryną z powodu przewlekłego zapalenia wątroby typu C. Interferon spowodował nadczynność tarczycy wymagającą zastosowania 
tyreostatyku. Tyreostatyki stosowane w leczeniu nadczynności tarczycy mogą być przyczyną agranulocytozy. Nie można wykluczyć ich 
synergistycznego działania z interferonem na szpik kostny. (Endokrynol Pol 2012; 63 (1): 52–55)
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Introduction
Acute agranulocytosis is a life-threatening condition 
diagnosed when the number of neutrophilic granulo-
cytes is lower than 500/µl. The condition is most often 
caused by medications, viral infections, chemotherapy, 
radiotherapy, autoimmune diseases, and bone marrow 
aplasia [1]. The cause of drug-induced agranulocytosis 
is the oversensitivity of bone marrow stem cells to some 
substances (idiosyncrasy) [2]. The clinical picture of 
acute agranulocytosis is most commonly characterised 
by fever, deterioration in general health status, and se-
vere oral mucosal ulceration quite often accompanied 
by bacterial, viral, fungal superinfection. The symptoms 
usually subside 5–10 days after withdrawal of the 
agranulocytosis-inducing drug [3]. 
This study presents two cases of acute agranulocytosis 
which occurred in patients with chronic hepatitis C treated 
with pegylated interferon (PegIFN) and ribavirin (RBV). 
In both cases, the interferon therapy was complicated by 
hyperthyreosis which required the use of an anti-thyroid 
drug. The aim of the study is to draw attention to the pos-
sible occurrence of the complication, and the necessity of 
cooperation between specialists in several medical fields, 
such as hepatologists, endocrinologists, and haematologists.
Case reports
Case no. 1
Female patient K.M., aged 27, chronically infected with 
genotype 1 HCV, was treated with pegylated interferon 
alpha 2a (PegIFN alpha 2a) at a dose of 180 µg once weekly 
and ribavirin at a dose of 1.0 g/day. Before the treatment, 
the HCV RNA value was 9.34 × 104 IU/ml and the TSH 
level was 2.8uIU/ml [normal (N): 0.25–5.0 uIU/ml]. The 
initial period of treatment proceeded without complica-
tions. Haematology results were within normal limits and 
the HCV viremia assessed in the fourth and 12th week of 
treatment was undetectable. In the 12th week of treatment, 
the patient reported epistaxis, cold symptoms without 
fever. Haematology test showed a decrease in the num-
ber of platelets to 72 × 103/µl. The dose of PegIFN alpha 
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2a was reduced to 135 µg. The subsequent haematology 
panels performed weekly showed an increase in the num-
ber of platelets (122 × 103/µl). However, leucopenia and 
granulocytopenia occurred (leukocytes — 2.1 × 103/µl, the 
absolute neutrophil count — ANC — 714/µl). The reduced 
dose of PegIFN alpha 2a was maintained. According to the 
applicable standards, in the 12th week of treatment, the 
TSH and thyroid hormones levels were determined and 
were: a decreased TSH level < 0.005 uIU/ml and thyroid 
hormones levels within normal limits: fT3 — 2.8 pg/ml 
(N: 2.60–5.40 pg/ml), fT4 — 0.97ng/ml (N: 0.69–1.55 ng/ml). 
Anti-TSH receptor antibody was negative. Thyroid sonog-
raphy showed homogenous echogenicity and normal 
volume of both thyroid lobes, and no tumours were found. 
In the 18th week of therapy, the full dose of interferon 
was reintroduced due to the satisfactory haematology re-
sult, and a week later treatment with an anti-thyroid drug 
began. Thiamazole was administered at a dose of 20 mg 
/day. Because of the drug intolerance (pain in the joints) 
after several days it was replaced by propylthiouracil at 
a dose of 50 mg /day. After six weeks of treatment, the 
patient was admitted to hospital because of fever, chills, 
severe sore throat and general weakness of one week’s 
duration. Physical examination showed fever of 38.5°C, 
skin paleness, and white fur on the deep red, swollen 
oral and tonsillar mucosa. Blood cultures and pharyngeal 
swabs were taken. The results of selected laboratory tests 
done during hospitalisation are presented in Table I. All 
medications were stopped. There was administered 
ciprofloxacin at a dose of 2 × 200 mg intravenously (i.v.) 
and fluconazole 1 × 200 mg orally. Due to agranulocyto-
sis, the patient received granulocyte colony-stimulating 
factor G-CSF (Neupogen) at a dose of 480 µg subcutane-
ously (s.c.). On the second day of hospitalization, the 
patient felt better, she did not have fever and the local 
pharyngeal lesions were less severe. On the following 
days, the pharyngeal and tonsillar lesions disappeared, 
and the physical condition of the patient improved. The 
pharyngeal swabs and blood cultures were negative. 
There were determined: TSH — 9.19 uIU/ml, fT4 — 
0.69 ng/ml, fT3 — 2.84 pg/ml. The patient was discharged 
from hospital in a good general condition. She remained 
under the care of an endocrinologist, who ended 
a one-month observation upon finding the patient in 
euthyreosis. The achievement of complete early viral 
response (cEVR) and low levels of initial HCV viremia, 
undetectable in the 24th week of treatment, justified the 
termination of the treatment with pegylated interferon 
alpha 2a and ribavirin. After six months of observation, 
HCV viremia was still undetectable (SVR) and the TSH 
and thyroid hormones levels, as well as complete blood 
count, were within normal limits.
Case no. 2
Female patient J.M., aged 52, treated for chronic hepatitis 
C with pegylated interferon alpha 2b (PegIFN alpha 2b) 
at a dose of 150 µg once a week and ribavirin at a dose of 
1.2 g/day. The patient was infected with genotype 1 HCV. 
Before the treatment, the HCV viremia level was 2.52 × 106 
IU/ml and the TSH level was 1.4 uIU/ml. Initially the 
treatment proceeded without complications. A decrease 
of viremia by 2 log10 (1.89 × 10
4 IU/ml) in the 12th week of 
therapy justified the continuation of the treatment. Due 
to anaemia (Hb 9.0 g/dl), the ribavirin dose was reduced 
Table I. The results of selected laboratory blood tests — case no. 1
Tabela I. Wyniki wybranych badań laboratoryjnych krwi — przypadek nr 1
Laboratory results (normal values) First day of hospitalisation
Second day 
of hospitalisation
Third day of hospitalisation 
(last day)
Hb (12–16 g/dL) 11.7 11.8 11.8
Platelets (140–440 × 103/µL) 108 112 120
Leukocytes (4–10 × 103/µL) 1.2 3.4 5.8
Bands (3–5%) 1 15 19
Segments (57–65%) 8 30 31
Lymphocytes (20–40%) 63 44 40
Monocytes (4–8%) 28 11 10
Eosinophils (2–4%) 0 0 0
Basophils (0–1%) 0 0 0
ANC (1800–8000/µL) 108 1530 2900
CRP (0–5 mg/dL) 5.0
PCT (<0.5 ng/mL) <0.5
Hb — haemoglobin; ANC — absolute neutrophil count; CRP — C-reactive protein; PCT — procalcitonin
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to 1.0 g/day. The TSH and thyroid hormones levels were 
within the normal range (TSH — 0.75 uIU/ml, fT4 — 
0.96 ng/ml). In the 20th week of treatment, the patient 
reported a decrease in exercise tolerance, irritability and 
insomnia. No progression of anaemia was found. TSH 
was 0.20 uIU/ml and fT4 was 1.07 ng/ml. The TSH level 
was determined again after five weeks. At that time, hy-
perthyreosis was diagnosed (TSH < 0.005 uIU/ml, fT4 
— 8.29 ng/ml) and the treatment with thiamazole at a dose 
of 20 mg/day was started. The interferon and ribavirin 
therapy was continued. After three weeks of taking thia-
mazole, the patient was admitted to hospital because of 
fever and chills of two days’ duration, severe sore throat, 
difficulty in swallowing and enlarged cervical lymph 
nodes. Physical examination showed fever of 38.2°C, 
skin paleness, enlarged, soft and painful cervical lymph 
nodes. The patient presented with lockjaw, dysphagia 
and ulceration of the oral mucosa. Pharyngeal swabs 
and blood cultures were taken. All medications were 
discontinued. There were administered: hydrocortisone 
at a daily dose of 150 mg i.v., fluconazole — 200 mg i.v., 
meropenem 1.0 g i.v. three times a day and granulocyte 
colony-stimulating factor G-CSF (Neupogen) at a dose of 
480 µg s.c. The general condition of the patient was stable, 
the sore throat and dysphagia were subsiding. On the 
third day of hospitalisation, the body temperature nor-
malised. Pharyngeal swabs and blood cultures were nega-
tive. On the fifth day, the patient was transferred to the 
haematology department, where the treatment described 
above was continued. During her stay on that ward the 
patient again experienced fever, of 39.0°C. Purulent pala-
tine tonsillitis was diagnosed. Enterococcus faecium was 
cultured from pharyngeal swabs and antibiotic was used 
according to the antibiogram result. The results of selected 
laboratory blood tests done during hospitalisation are 
presented in Table II. In the following three months of 
observation, the thyroid function returned to normal 
and the patient did not require further treatment. The 
treatment with PegIFN alpha 2b and ribavirin was not 
reinitiated due to its ineffectiveness (HCV RNA in the 
24th week of treatment — 2.90 × 106 IU/ml). 
Discussion
Recombinant or pegylated interferon alpha used in 
the treatment of chronic hepatitis C causes thyroid 
function disorders with an estimated incidence of be-
tween 5% and 15% [4]. Among factors predisposing to 
their development are female sex and the presence of 
antithyroid antibodies. The risk of developing thyroid 
dysfunctions in patients who had TPOAb before treat-
ment is 46.1% compared to 5.4% in patients without 
these antibodies [5, 6]. It is recommended that TSH, fT4, 
TPOAb and TgAb levels be determined before treat-
ment. During the treatment, the TSH test is repeated 
every 12 weeks in patients with a normal TSH level 
and without the antibodies, or every eight weeks if the 
antibodies are present [5, 7]. Hyperthyreosis occurs less 
frequently than hypothyreosis [8]. In the presented 
cases, hyperthyreosis developed in the 12th and 25th 
week of treatment with pegylated interferon alpha 2a 
and 2b respectively. In Poland the first-choice drug to 
treat hyperthyreosis is thiamazole. Propylthiouracil is 
reserved for patients with allergy to thiamazole and 
Table II. The results of selected laboratory blood tests — case no. 2
Tabela II. Wyniki wybranych badań laboratoryjnych krwi — przypadek nr 2
Laboratory results (normal values) First day of hospitalisation 
Third day 
of hospitalisation
Twelfth day of hospitalisation 
(last day)
Hb (12–16 g/dL) 9.6 8.0 12.2
Platelets (140–440 × 103/µL) 196 183 261
Leukocyte (4–10 × 103/µL) 0.8 1.0 5.4
Bands (3–5%) 0 0 8
Segments (57–65%) 2 0 25
Lymphocytes (20–40%) 97 99 56
Monocytes (4–8%) 1 1 11
Eosinophils (2–4%) 0 0 0
Basophils (0–1%) 0 0 0
ANC (1800–8000/µL) 16 0 1782
CRP (0–5 mg/dL) 347 28
PCT (< 0.5 ng/mL) 1.26 < 0.5
Hb — haemoglobin; ANC — absolute neutrophil count; CRP — C-reactive protein; PCT — procalcitonin
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for women in the first trimester of pregnancy [9, 10]. In 
both patients, thiamazole was used at first. However, 
in patient 1 due to the drug-intolerance it was replaced 
by propylthiouracil. Medications were administered at 
full dose, which resulted in euthyreosis. 
A rare adverse drug reaction (affecting 0.2–0.5% of 
patients) is agranulocytosis [9]. In the discussed cases 
1 and 2 it developed in the first three months of treat-
ment with ATD and was of moderate and severe forms 
respectively. Anti-thyroid drugs were found to be the 
likely cause of agranulocytosis, although at the same 
time there were used two medications inducing bone 
marrow damage. Interferon alpha has a suppressive 
effect on bone marrow but agranulocytosis has never 
been reported while using the drug. In the registration 
study with pegylated interferon alpha 2b at a dose of 
1.5 µg/kg/week and ribavirin, the necessity to reduce 
the dose due to neutropenia was 18%. Simultaneously, 
in less than 1% of patients the therapy was discontinued 
for that reason. In the registration study with pegylated 
interferon alpha 2a at a dose of 180 µg/week and ribavi-
rin, the necessity to modify the dose due to neutropenia 
was 17% and only four patients (< 0.5%) terminated the 
therapy prematurely [12]. In Polish studies, neutropenia 
was the reason for discontinuation of the treatment in 
0.6% of patients [13]. According to current guidelines, it is 
recommended to reduce the dose of pegylated interferon 
if the number of neutrophils falls below 750/mm3, and to 
discontinue it altogether if the number is < 500/mm3 [14]. 
These recommendations protect against the occurrence 
of agranulocytosis. Agranulocytosis prevention during 
the treatment with ATD consists in the frequent control 
of the leukogram. The number of neutrophils that suggest 
that the therapy should be discontinued is not clearly 
defined. Despite frequently performed haematology tests 
in the presented cases, the complication was not avoided. 
Granulocyte colony-stimulating factor was used in the 
treatment. It is said to be effective, though its effectiveness 
has not been unequivocally proved [9]. 
Hepatotoxic effects of anti-thyroid drugs were not 
observed in the female patients. Both imidazole and 
thiouracyl derivatives can cause drug-induced liver 
injury [15, 16]. Thiamazole induces mainly dose-de-
pendent cholestasis, while propylthiouracyl induces 
dose-independent hepatitis. A communication issued 
by the FDA in June 2009 includes information on the 
heightened risk of severe liver injury after the use of 
propylthiouracil compared to thiamazole. In a case of 
treatment with the medication, it is recommended that 
patients be monitored for liver injury, particularly dur-
ing the first six months of therapy [17]. 
In the cases discussed, close co-operation between 
the doctors treating patients with chronic HCV infec-
tion (in Poland mainly infectious disease specialists), 
endocrinologists and haematologists was necessary. 
Adverse drug reactions during interferon therapy, in 
particular thyroid dysfunction, require working closely 
with endocrinologists and making joint decisions as to 
continuation or discontinuation of treatment. The as-
sistance of haematologists is indispensable in cases of se-
vere agranulocytosis, when it is necessary to exclude its 
other causes and begin treatment with growth factors. 
Conclusions
1. Anti-thyroid drugs used in the treatment of hyper-
thyreosis, being a complication after interferono-
therapy, can cause agranulocytosis.
2. A synergistic effect of ATD and interferon on bone 
marrow cannot be excluded.
3. In a case of the occurrence of hyperthyreosis treated 
with ATD, the decision as to continuation or discon-
tinuation of the antiviral therapy should be taken 
jointly by the doctor treating the patient with chronic 
HCV infection and an endocrinologist.
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